Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy

doi:10.3389/fimmu.2024.1488345

. 2024 Dec 6:15:1488345.

doi: 10.3389/fimmu.2024.1488345. eCollection 2024.

Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy

Xiaoyan Qi^{1

2}, Cheng Cheng^{1

3}, Dawei Zhang^{1

4}, Zongjiang Yu⁵, Xiangwei Meng^{1

6}

Affiliations

¹ Zibo Central Hospital, Zibo, China.
² Department of Oncology, Zibo Central Hospital, Zibo, China.
³ Department of Cardiology, Zibo Central Hospital, Zibo, China.
⁴ Department of Orthopedics, Zibo Central Hospital, Zibo, China.
⁵ CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao, China.
⁶ Department of Drug Clinical Trials, Zibo Central Hospital, Zibo, China.

PMID: 39712021
PMCID: PMC11659200
DOI: 10.3389/fimmu.2024.1488345

Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy

Xiaoyan Qi et al. Front Immunol. 2024.

. 2024 Dec 6:15:1488345.

doi: 10.3389/fimmu.2024.1488345. eCollection 2024.

Authors

Xiaoyan Qi^{1

2}, Cheng Cheng^{1

3}, Dawei Zhang^{1

4}, Zongjiang Yu⁵, Xiangwei Meng^{1

6}

Affiliations

¹ Zibo Central Hospital, Zibo, China.
² Department of Oncology, Zibo Central Hospital, Zibo, China.
³ Department of Cardiology, Zibo Central Hospital, Zibo, China.
⁴ Department of Orthopedics, Zibo Central Hospital, Zibo, China.
⁵ CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao, China.
⁶ Department of Drug Clinical Trials, Zibo Central Hospital, Zibo, China.

PMID: 39712021
PMCID: PMC11659200
DOI: 10.3389/fimmu.2024.1488345

No abstract available

Keywords: STING agonists; cancer immunotherapy; immune suppression; macrophage polarization; tumor microenvironment (TME).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

**Figure 1**
Schematic illustration of the TME and the STING pathway, and their synergy. The TME consists of various components including tumor cells, macrophages (TAMs, with M1 and M2 phenotypes), regulatory Tregs, MDSCs, and ECM. The STING pathway is activated by cytosolic DNA, leading to the production of IFNs and activation of DCs and T cells. The synergy between TME modulation (such as reprogramming TAMs from M2 to M1, and targeting MDSCs) and STING agonists is shown, with arrows indicating the interactions and effects on immune responses and tumor cells.

See this image and copyright information in PMC

References

1. Colley A, Brauns T, Sluder AE, Poznansky MC, Gemechu Y. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy. Trends Mol Med. (2024) 30:765–80. doi: 10.1016/j.molmed.2024.05.001 - DOI - PubMed
1. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. (2022) 19:254–67. doi: 10.1038/s41571-022-00600-w - DOI - PMC - PubMed
1. Zemek RM, Anagnostou V, Pires da Silva I, Long GV, Lesterhuis WJ. Exploiting temporal aspects of cancer immunotherapy. Nat Rev Cancer. (2024) 24:480–97. doi: 10.1038/s41568-024-00699-2 - DOI - PubMed
1. Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, et al. . Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. (2023) 14:1167975. doi: 10.3389/fimmu.2023.1167975 - DOI - PMC - PubMed
1. Li Y, Xiang S, Pan W, Wang J, Zhan H, Liu S. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective. Front Oncol. (2023) 13:1166860. doi: 10.3389/fonc.2023.1166860 - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources
- Frontiers Media SA
- PubMed Central
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Colley A, Brauns T, Sluder AE, Poznansky MC, Gemechu Y. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy. Trends Mol Med. (2024) 30:765–80. doi: 10.1016/j.molmed.2024.05.001 - DOI - PubMed

[2] Colley A, Brauns T, Sluder AE, Poznansky MC, Gemechu Y. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy. Trends Mol Med. (2024) 30:765–80. doi: 10.1016/j.molmed.2024.05.001 - DOI - PubMed

[3] Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. (2022) 19:254–67. doi: 10.1038/s41571-022-00600-w - DOI - PMC - PubMed

[4] Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. (2022) 19:254–67. doi: 10.1038/s41571-022-00600-w - DOI - PMC - PubMed

[5] Zemek RM, Anagnostou V, Pires da Silva I, Long GV, Lesterhuis WJ. Exploiting temporal aspects of cancer immunotherapy. Nat Rev Cancer. (2024) 24:480–97. doi: 10.1038/s41568-024-00699-2 - DOI - PubMed

[6] Zemek RM, Anagnostou V, Pires da Silva I, Long GV, Lesterhuis WJ. Exploiting temporal aspects of cancer immunotherapy. Nat Rev Cancer. (2024) 24:480–97. doi: 10.1038/s41568-024-00699-2 - DOI - PubMed

[7] Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, et al. . Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. (2023) 14:1167975. doi: 10.3389/fimmu.2023.1167975 - DOI - PMC - PubMed

[8] Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, et al. . Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. (2023) 14:1167975. doi: 10.3389/fimmu.2023.1167975 - DOI - PMC - PubMed

[9] Li Y, Xiang S, Pan W, Wang J, Zhan H, Liu S. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective. Front Oncol. (2023) 13:1166860. doi: 10.3389/fonc.2023.1166860 - DOI - PMC - PubMed

[10] Li Y, Xiang S, Pan W, Wang J, Zhan H, Liu S. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective. Front Oncol. (2023) 13:1166860. doi: 10.3389/fonc.2023.1166860 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy

Affiliations

Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

References

LinkOut - more resources

Full Text Sources

Research Materials